Emerging therapies will drive prostate cancer drug market to $10.1 billion in 2020

Driven by the launches of several promising emerging therapies, the prostate cancer drug market will experience robust growth over the next decade, increasing from $3.6 billion in 2010 to $10.1 billion in 2020 in the USA, France, Germany, Italy, Spain, the UK and Japan, says advisory firm Decision Resources.

The findings from DR’s Pharmacor topic titled Prostate Cancer reveal that eight of the nine emerging therapies that are forecast to launch through 2020 will enter the metastatic castrate-resistant prostate cancer setting, including the launch of Johnson & Johnson/Janssen Biotech/Janssen-Cilag’s Zytiga (abiraterone acetate) in 2011.

Owing to its efficacy, favorable safety and tolerability profile, convenient delivery and physician familiarity with hormonal agents, Zytiga will experience rapid and widespread uptake. In prostate cancer patients who have previously received docetaxel, Medivation/Astellas Pharma’s MDV-3100 has shown comparable median overall survival benefit to Zytiga and both agents - MDV-3100 and Zytiga - are poised to transform the prostate cancer drug market.